<DOC>
	<DOCNO>NCT01955564</DOCNO>
	<brief_summary>This prospective , 8-day , randomize , double-blind , placebo-controlled , sequential-cohort study design evaluate safety , tolerability , MTD single escalate oral dos NW-3509A healthy male volunteer . Six independent cohort 12 volunteer participate study , first 9 volunteer cohort qualify randomize receive study medication remain 3 used backups/ alternate . In cohort , 6 subject randomly assign receive NW-3509A 3 subject receive placebo .</brief_summary>
	<brief_title>A Phase I- Sequential Cohort Dosing Determine Maximum Tolerated Dose Healthy Male Volunteers .</brief_title>
	<detailed_description>Doses 1 30 mg test</detailed_description>
	<criteria>Demographics Volunteers meet follow demographic inclusion criterion : 1 . Age 18 45 year age , inclusive . 2 . Sex male . 3 . The subject body weight least 45 kg body mass index ≤30 . Procedural Volunteers meet follow procedural criterion : 4 . They cooperative , able take oral medication , willing complete aspect study , capable . 5 . They able understand instruction fully participate . 6 . They provide write informed consent prior participate study . 7 . The subject good health history significant medical disease determine investigator . The presence follow exclude subject study enrollment : General Medical Status 1 . An advanced , severe , unstable disease type may interfere study evaluation , include medical condition could expect progress , recur , change extent may bias assessment clinical mental status volunteer significant degree put volunteer special risk ( e.g. , liver kidney disease ; malignancy ) ; 2 . A disability may prevent volunteer complete study requirement ( e.g. , blindness , deafness , severe language difficulty ) ; 3 . A current diagnosis active , uncontrolled peptic ulceration within last year ; 4 . A current diagnosis acute , severe , unstable asthmatic condition . Cardiovascular 5 . A current diagnosis severe unstable cardiovascular disease ; 6 . A current diagnosis sicksinus syndrome conduction deficit ( e.g. , sinoatrial block ( &lt; 0.22 ) , second third degree atrioventricular block ) ; 7 . Any history current evidence cardiac illness determine investigator ; 8 . Any clinically significant ECG abnormality , include disorder rate , rhythm , conduction , morphological change , QTcF interval ( Fridericia 's correction formula ) ECG &gt; 450 msec . The 12lead ECG use determine suitability subject inclusion study ( determined investigator ) ; 9 . Vital sign ( supine ) outside follow range : Systolic blood pressure 100 139 mmHg ; Diastolic blood pressure 50 89 mmHg ; Radial pulse 50 90 bpm . CNS relate 10 . Any history current diagnosis neurodegenerative illness ; 11 . History current diagnosis epilepsy seizure disorder . Psychiatric 12 . Any past current psychiatric illness ( DSMIVTR Axis 1 diagnosis ) ; 13 . Subjects current past suicidal ideation . Studyspecific criteria 14 . History serious adverse reaction hypersensitivity drug ; 15 . Presence history allergy require acute chronic treatment ( except seasonal allergic rhinitis ) ; 16 . Alcohol drug abuser ; currently time last 5 year ; 17 . Abnormal physical finding clinical significance screen examination baseline would interfere objective study ; 18 . Need prescription medication within 14 day prior administration study drug , and/or nonprescription medication within 7 day prior administration drug ; 19 . Participation clinical trial last 2 month investigational drug commercially available drug test ; 20 . Loss 500 ml blood 3month period study , e.g . donor . 21 . Existence surgical medical condition might interfere absorption , distribution , metabolism excretion study drug , i.e . impaired renal hepatic function , diabetes mellitus , cardiovascular abnormality , inflammatory bowel disease , chronic symptom pronounce constipation diarrhea , condition associate total partial obstruction urinary tract ; 22 . Symptoms significant somatic mental illness fourweek period precede study drug administration ; 23 . History hepatitis B and/or C , and/or positive serology result , indicate presence hepatitis B and/or C ( Hepatitis B surface antigen and/or antibody Hepatitis C ) ; 24 . Positive result HIV serology ; 25 . Positive result drug alcohol test screen and/or checkin unit ; 26 . Smoker ; currently time last 5 year ; Laboratory abnormalities 27 . Clinically significant abnormality routine laboratory examination ( hematology ; blood chemistry , include electrolyte liver kidney function test ; urinalysis ) , determine Principal Investigator consultation Sponsor , screen evaluation ; 28 . Clinically important laboratory abnormality thyroid function test screen : • TSH &gt; 8.0 mU/L and/or Free T4 &lt; 9 pmol/L ; Concomitant therapy 29 . A know exaggerated pharmacological sensitivity hypersensitivity drug similar NW3509A . Possible examples volunteer experience hypersensitivity reaction sodium channel blocker ; 30 . Ingested follow substance : An investigational drug past 2 month ; A drug treatment know cause major organ system toxicity past year ; Any prescription drug OTC product take continuously ( Medical Monitor Newron contact Investigator want include volunteer take OTC product ) ; Alcohol intake limited 2 drink per day 2 week prior dose ; alcohol consumption prohibit 72 hour prior admittance Day 1 final safety evaluation Day 8 . Caffeinecontaining product limit ( equivalent 2 cup coffee per day ) 2 week prior dose final safety evaluation Day 8 .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>